Literature DB >> 937182

Influence of dobutamine on hemodynamics and coronary blood flow in patients with and without coronary artery disease.

S L Meyer, G C Curry, M S Donsky, D B Twieg, R W Parkey, J T Willerson.   

Abstract

The influence of dobutamine on hemodynamics and coronary blood flow was studied in patients after routine cardiac catheterization. The data demonstrated that dobutamine is a powerful inotropic agent at a dose that has a relatively small influence on heart rate. In patients without coronary artery disease dobutamine greatly increased coronary arterial perfusion. In patients with severe coronary artery diseases dobutamine resulted in a much smaller increase in coronary perfusion, and the pattern of perfusion became more inhomogeneous. The results suggest that dobutamine has a potential inotropic value but raise concern about its influence on regional myocardial perfusion in patients with serious coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 937182     DOI: 10.1016/0002-9149(76)90070-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

1.  Myocardial oxidative metabolism in normal subjects in fasting, glucose loading and dobutamine infusion states.

Authors:  N Tamaki; Y Magata; N Takahashi; M Kawamoto; T Torizuka; Y Yonekura; S Nishizawa; N Sadato; E Tadamura; S Ono
Journal:  Ann Nucl Med       Date:  1992-11       Impact factor: 2.668

2.  Tolerance, hemodynamic changes, and safety of dobutamine stress perfusion imaging.

Authors:  H A Dakik; H Vempathy; M S Verani
Journal:  J Nucl Cardiol       Date:  1996 Sep-Oct       Impact factor: 5.952

3.  Metabolic reserve in normal myocardium assessed by positron emission tomography with C-11 palmitate.

Authors:  N Tamaki; M Kawamoto; N Takahashi; Y Yonekura; Y Magata; R Nohara; H Kambara; C Kawai; J Konishi
Journal:  Ann Nucl Med       Date:  1991-07       Impact factor: 2.668

4.  Dobutamine echocardiography predicts functional outcome after revascularisation in patients with dysfunctional myocardium irrespective of the perfusion pattern on resting thallium-201 imaging.

Authors:  R Senior; A Lahiri
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

5.  Oxidative metabolism in the myocardium in normal subjects during dobutamine infusion.

Authors:  N Tamaki; Y Magata; N Takahashi; M Kawamoto; T Torizuka; Y Yonekura; E Tadamura; K Okuda; S Ono; R Nohara
Journal:  Eur J Nucl Med       Date:  1993-03

Review 6.  Inotropic agents in the treatment of cardiogenic shock.

Authors:  H S Mueller
Journal:  World J Surg       Date:  1985-02       Impact factor: 3.352

7.  Pharmacological treatment of pulmonary oedema.

Authors:  J Carlet; M Francoual; F Lhoste; B Regnier; F Lemaire
Journal:  Intensive Care Med       Date:  1980       Impact factor: 17.440

8.  Systemic and regional myocardial responses to AR-L 115 BS, a positive inotropic imidazo-pyridine, in the absence or in the presence of the bradycardiac action of alinidine.

Authors:  P D Verdouw; J M Hartog; A M Ruggeman
Journal:  Basic Res Cardiol       Date:  1981 May-Jun       Impact factor: 17.165

9.  Identification of asynergic but viable myocardium in patients with chronic coronary artery disease by gated blood pool scintigraphy during isosorbide dinitrate and low-dose dobutamine infusion: comparison with thallium-201 scintigraphy with reinjection.

Authors:  H Matsuo; S Watanabe; Y Nishida; T Matsubara; M Kano; S Tanihata; Y Matsuno; H Oda; Y Kotoo; H Oohashi
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

10.  Dobutamine 99mTc-MIBI single-photon emission tomography: non-exercise-dependent detection of haemodynamically significant coronary artery stenoses.

Authors:  E Voth; F M Baer; P Theissen; C A Schneider; U Sechtem; H Schicha
Journal:  Eur J Nucl Med       Date:  1994-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.